Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice

Journal of Neural Transmission

Volumn 113, Issue 2, 2006, Pages 137-150

  Fredriksson, A ^a   Eriksson, P ^a   Archer, T ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Basal ganglia; C57 BL6 mice; Clozapine; DA D2 receptor supersensitivity; Fe2+; Haloperidol; Iron administration; Locomotion; Parkinsonism; Postnatal; Rearing; Total activity; Vehicle

Indexed keywords

APOMORPHINE; CLOZAPINE; FERROUS SUCCINATE; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REARING; RECEPTOR SENSITIVITY; RESPONSE TIME;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BASAL GANGLIA; CLOZAPINE; DOPAMINE AGONISTS; DRUG INTERACTIONS; FEMALE; HALOPERIDOL; HYPERKINESIS; IRON; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PREGNANCY;

EID: 31044450697     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0307-3     Document Type: Article

References (50)

1. T Archer A Fredriksson G Jonsson T Lewander AK Mohammed SB Ross U Soderberg 1986 Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology 88 141 146
2. T Archer N Schröder A Fredriksson 2003 Neurobehavioural deficits following postnatal iron overload. II. Instrumental learning performance. Neurotox Res 5 77 94
3. D Ben-Shachar MB Youdim 1990 Neuroleptic-induced supersensitivity and brain iron. I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity. J Neurochem 54 1136 1141
4. D Ben-Shachar E Livne I Spanier R Zuk MB Youdim 1993 Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr J Med Sci 29 587 592
5. D Ben-Shachar B Pinhassi MB Youdim 1991 Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment. Eur J Pharmacol 202 177 183
6. RG Bolles PJ Woods 1964 The ontogeny of behaviour in the albino rat. Anim Behav 12 427 441
7. A Campbell RJ Baldessarini 1981 Tolerance to behavioural effects of haloperidol. Life Sci 29 1341 1346
8. BA Campbell LD Lytle HC Fibiger 1969 Ontogeny of adrenergic arousal and cholinergic inhibitory mechanisms in the rat. Science 166 635 637
9. Davison AN, Dobbing J (1968) Applied neurochemistry. Blackwell, Oxford, pp 178-221, 253-316
10. DT Dexter A Carayon F Javoy-Agid Y Agid FR Wells SE Daniel AJ Lees P Jenner CD Marsden 1991 Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 1953 1975
11. DT Dexter FR Wells F Agid Y Agid AJ Lees P Jenner CD Marsden 1987 Increased nigral iron content in postmortem parkinsonian brain [letter]. Lancet 2 1219 1220
12. BP Drayer W Olanow P Burger GA Johnson R Herfkens S Riederer 1986 Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 159 493 498
13. AJ Dwork G Lawler PA Zybert M Durkin M Osman N Willson AI Barkai 1990 An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res 518 31 39
14. PH Evans 1993 Free radicals in brain metabolism and pathology. Br Med Bull 49 577 587
15. A Fredriksson N Schroder T Archer 2003 Neurobehavioural deficits following postnatal iron overload. I. Spontaneous motor activity. Neurotoxicity Res 5 53 76
16. A Fredriksson N Schroder P Eriksson I Izquierdo T Archer 1999 Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol Appl Pharmacol 159 25 30
17. A Fredriksson N Schroder P Eriksson I Izquierdo T Archer 2000 Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Brain Res Dev Brain Res 119 65 74
18. A Fredriksson N Schroder P Eriksson I Izquierdo T Archer 2001 Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Rel Dis 7 97 105
19. M Gerlach D Ben-Shachar P Riederer MB Youdim 1994 Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63 793 807
20. J Glowinski LL Iversen 1966 Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 13 655 669
21. MM Iqbal A Rahman Z Husain SZ Mahmud WG Ryan JM Feldman 2003 Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiat 15 33 48
22. Janetzky B, Reichmann H, Youdim MBH, Riederer P (1997) Iron and oxidative damage in neurodegenerative diseases. In: Beal MF, Howell H, Bodis-Wollner I (eds) Wiley-Liss, New York, pp 407-421
23. E Kienzl L Puchinger K Jellinger W Linert H Stachelberger RF Jameson 1995 The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci 134 Suppl 69 78
24. Kirk R (1995) Experimental design: procedures for the behavioural sciences. Brooks/Cole, Belmont, CA
25. P Laduron K De Bie J Leysen 1977 Specific effect of haloperidol on dopamine turnover in the frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 296 183 185
26. JA Lieberman 1998 Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 59 38 43
27. DC Mash J Pablo BE Buck J Sanchez-Ramos WJ Weiner 1991 Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp Neurol 114 73 81
28. T Matsumoto H Uchimura M Hirano J Soo Kim H Yokoo M Shimomura T Nakahara K Inoue K Oomagari 1983 Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete levels of rat brain. Eur J Pharmacol 89 27 33
29. RG McKenzie MJ Zigmond 1985 Chronic neuroleptic treatment increased D-2 but not D-1 receptors in the rat striatum. Eur J Pharmacol 113 159 165
30. HR Meltzer S Matsubara JC Lee 1989 Classification of typical and atypical antipsychotic drugs on the basis of D1-D2 and serotonin PK1 values. J Pharmacol Exp Ther 251 3238 3246
31. CW Olanow 1992 Magnetic-resonance-imaging in parkinsonism. Neurol Clin 10 405 420
32. PK Randall 1985 Quantification of dopaminergic supersensitivity using apomorphine induced behaviour in the mouse. Life Sci 37 1419 1423
33. PK Randall JA Severson CE Finch 1981 Aging and the regulation of striatal dopaminergic mechanisms in mice. J Pharmacol Exp Ther 219 695 700
34. H Reichmann B Janetzky P Riederer 1995 Iron-dependent enzymes in Parkinson's disease. J Neural Transm (Suppl) 46 157 164
35. GP Reynolds JE Brown JE McCall AVP McKay 1992 Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a postmortem study. J Neural Transm 87 225 230
36. E Richelson A Elson 1984 Antagonism of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103 197 214
37. P Riederer E Sofic WD Rausch B Schmidt GP Reynolds K Jellinger MB Youdim 1989 Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 515 520
38. Rozenzweig MR, Leiman AL, Breedlove SM, (1999) Biological psychology: an introduction to behavioural, cognitive and clinical neuroscience. Sinauer, Sunderland, MA
39. B Scatton 1977 Differential regional development of the tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur J Pharmacol 46 363 369
40. N Schroder A Fredriksson M Vianna R Roesler I Izquierdo T Archer 2001 Memory deficits in adult rats following postnatal iron administration. Behav Brain Res 124 77 85
41. Strong R, Mattamal M, Andorn A (1993) Free radicals in aging. In: Yu B (ed) Free radicals, the aging brain, and age-related neurodegenerative disorders. CRC Press, Florida, pp 223-246
42. KF Swaiman 1991 Hallervorden-Spatz syndrome and brain iron metabolism. Arch Neurol 48 1285 1293
43. D Tarsy RJ Baldessarini 1974 Behavioural supersensitivity to apomorphine following treatment with drugs which interfere with synaptic function of catecholamines. Neuropharmacology 13 927 940
44. EM Taylor EH Morgan 1990 Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res Dev Brain Res 55 35 42
45. EM Taylor A Crowe EH Morgan 1991 Transferrin and iron uptake by the brain: effects of altered iron status. J Neurochem 57 1584 1592
46. JL Waddington 1990 Neuroleptic/dopamine receptors. Eur J Pharmacol 183 106
47. PF Von Voigtlander EG Losey HF Triezenberg 1975 Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther 193 88 94
48. MB Youdim D Ben-Shachar P Riederer 1991 Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 31 34 40
49. MB Youdim D Ben-Shachar P Riederer 1993 The possible role of iron in the etiopathology of Parkinson's disease [published erratum appears in Mov Disord (1993) 8(2): 255]. Mov Disord 8 1 12
50. MB Youdim E Grunblatt S Mandel 1999 The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann NY Acad Sci 890 7 25